<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467646</url>
  </required_header>
  <id_info>
    <org_study_id>HRJC-CTO18</org_study_id>
    <nct_id>NCT03467646</nct_id>
  </id_info>
  <brief_title>Long-term Follow up After SG vs RYGB vs OAGB</brief_title>
  <official_title>Long-term Follow up After Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass Versus One-Anastomosis Gastric Bypass: A Comparative Study of Weight Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Elche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General Universitario Elche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized clinical study of all morbidly obese patients undergoing SG, RYGB&#xD;
      and OAGB, as primary bariatric procedures, was performed. Patients were randomly assigned&#xD;
      into 3 groups: those patients undergoing SG, those ones undergoing RYGB and those ones&#xD;
      undergoing OAGB. BMI, excess BMI loss (EBMIL) and remission of type 2 diabetes (T2DM),&#xD;
      hypertension (HT) and dyslipidemia (DL) were assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized clinical study of all morbidly obese patients undergoing SG, RYGB&#xD;
      and OAGB, as primary bariatric procedures, was performed. Patients were randomly assigned&#xD;
      into 3 groups: those patients undergoing Sleeve Gastrectomy, those ones undergoing Roux-en-Y&#xD;
      Gastric Bypass and those ones undergoing One-Anastomosis Gastric Bypass. Body Mass Index&#xD;
      (BMI), excess BMI loss (EBMIL) and remission of type 2 diabetes (T2DM), hypertension (HT) and&#xD;
      dyslipidemia (DL) were assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2010</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>1 , 2 and 5 years after surgery</time_frame>
    <description>The postoperative weight loss is investigated at 1, 2 and 5 years after surgery</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Sleeve Gastrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo a laparoscopic sleeve gastrectomy as bariatric procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roux-en-Y gastric bypass</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo a laparoscopic Roux-en-Y gastric bypass as bariatric procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One-Anastomosis gastric bypass</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo a laparoscopic One-Anastomosis gastric bypass as bariatric procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sleeve Gastrectomy</intervention_name>
    <description>The patients undergo a Sleeve Gastrectomy as bariatric procedure</description>
    <arm_group_label>Sleeve Gastrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-Y gastric bypass</intervention_name>
    <description>The patients undergo a Roux-en-Y gastric bypass as bariatric procedure</description>
    <arm_group_label>Roux-en-Y gastric bypass</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>One-Anastomosis Gastric Bypass</intervention_name>
    <description>The patients undergo a One-Anastomosis Gastric Bypass as bariatric procedure</description>
    <arm_group_label>One-Anastomosis gastric bypass</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  body mass index (BMI) &gt;40 Kg/m2&#xD;
&#xD;
          -  BMI &gt; 35 Kg/m2 with the presence of comorbidities associated to obesity&#xD;
&#xD;
          -  age older than 18 years&#xD;
&#xD;
          -  Patients willing to participate in the study and giving their written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients undergoing other bariatric techniques than SG, RYGB and OAGB&#xD;
&#xD;
          -  Patients undergoing any other surgical procedure added to the bariatric surgery&#xD;
&#xD;
          -  patients with medical or surgical pathologies that at the discretion of the&#xD;
             investigators do not allow their participation in the study&#xD;
&#xD;
          -  inability to understand the nature and purpose of the study and / or to accept written&#xD;
             participation in the study&#xD;
&#xD;
          -  impossibility to comply with pre-established clinical follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Angel Carbajo</last_name>
    <role>Study Director</role>
    <affiliation>Centro de Tratamiento de la Obesidad</affiliation>
  </overall_official>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 10, 2018</study_first_submitted>
  <study_first_submitted_qc>March 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 10, 2018</last_update_submitted>
  <last_update_submitted_qc>March 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Elche</investigator_affiliation>
    <investigator_full_name>Jaime Ruiz-Tovar, MD, PhD</investigator_full_name>
    <investigator_title>Head of Bariatric Surgery Unit. Hospital general Elche</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

